Lauren Sabella Joins Mannkind as Executive Vice President, Chief Operating Officer
DANBURY, Conn., March 27, 2023 (GLOBE NEWSWIRE) — MannKind Corporation (Nasdaq:MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced Lauren Sabella has joined the company as Executive Vice President, Chief Operating Officer, effective today. Sabella will report directly to Michael Castagna, PharmD, Chief Executive Officer, and serve on the company’s executive leadership team.
Related news for (MNKD)
- Cybersecurity Surges, Biotech Booms & SaaS Shifts- 7 Hot Stocks Lighting Up into the Close
- 24/7 Market News Snapshot 27 August, 2025 – Mannkind Corporation (NASDAQ:MNKD)
- MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
- MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
- MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association’s 85th Scientific Sessions in Chicago, June 20-23